SUMITOMO PHARMA CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 410 JPY | +2.50% |
|
+5.40% | -12.02% |
| 04-22 | Lull in Geopolitical Tensions Lifts Asian Stock Markets | MT |
| 04-17 | Jefferies Adjusts Sumitomo Pharma’s Price Target to 420 Yen From 520 Yen, Keeps at Hold | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company appears to be poorly valued given its net asset value.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Most analysts recommend that the stock should be sold or reduced.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -12.02% | 1.03B | B | ||
| +25.83% | 661B | C+ | ||
| +27.00% | 566B | B | ||
| -6.76% | 352B | C+ | ||
| +20.34% | 332B | B- | ||
| +3.00% | 283B | C+ | ||
| +13.09% | 231B | B+ | ||
| +5.46% | 200B | B- | ||
| -9.61% | 195B | A+ | ||
| -6.26% | 145B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4506 Stock
- Ratings Sumitomo Pharma Co., Ltd.
